Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK8141 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Arm 1: Drug 250 mg |
| 2 | EXPERIMENTAL | Arm 2: Drug 500 mg |
| 3 | ACTIVE_COMPARATOR | Arm 3: Active Comparator |
| 4 | PLACEBO_COMPARATOR | Arm 4: Pbo Comparator |
| Name | Type | Description |
|---|---|---|
| MK8141 | DRUG | MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period |
| Comparator: placebo (unspecified) | DRUG | MK8141 Pbo tablet once daily. 4 week treatment period. |
| Enalapril | DRUG | Enalapril 20 mg tablet once daily. 4 week treatment period. |
Inclusion Criteria: * You are 35 to 65 years of age * In the past 14 days you have not been treated for hypertension * In the past 14 days you have not taken more than 2 medications to treat high blood pressure * You are a woman who is not able to have children or do not use birth control Exclusio...
MK8141 is an investigational small molecule being studied for the treatment of hypertension, also known as high blood pressure. It is being developed by Merck & Company, Inc. (ticker: MRK). As of now, MK8141 is in Phase 2 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of MK8141 is not disclosed in the available information. Therefore, the exact mechanism of action for this investigational drug has not been publicly detailed. MK8141 is being studied for its effectiveness and tolerability in patients with high blood pressure.
MK8141 is being developed by Merck & Company, Inc., a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical trials to evaluate the safety and efficacy of MK8141 for the treatment of hypertension.
MK8141 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study involving 160 participants with hypertension. MK8141 is still investigational and has not received FDA approval.
MK8141 has one completed clinical trial registered under NCT00543413, titled "A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)." This Phase 2 study enrolled 160 participants with hypertension and was placebo-controlled.
No alternative names for MK8141 have been disclosed in the available information. It is identified solely by its development code MK8141, and no other names or aliases have been reported for this investigational compound.